News for BioVaxys Technology Corp. (BVAXF)

BioVaxys Technology Corp. (BVAXF) announces a 10:1 share consolidation, reducing outstanding shares from 293,425,203 to approximately 29,342,520 Common Sha

BioVaxys Technology Corp. (BIOV) amends Asset Purchase Agreement with Horizon Technology Finance Corporation. Key milestones lowered from USD $10M to US

PR NewswireVANCOUVER, BC, May 29, 2025 The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. AssetsVANCOUVER, BC, May 29, 2025 /

BioVaxys Technology Corp. (BVAXF) and Sona Nanotech Inc. have entered into a research collaboration to develop new cancer therapeutics using BioVaxys' DPXâ

February 28, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks added ...

PR NewswireVANCOUVER, BC, Jan. 16, 2025 VANCOUVER, BC, Jan. 16, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioV

**media[515642]**

MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Co

**media[514522]**

**media[483102]**

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

**media[481925]**

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging...

BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. today announced that the Ontario Securities Commission , as the Company's principal regulator, on February 29, 2024,...

- Fourth Quarter 2023 Net Investment Income per Share of $0.45; NAV per Share of $9.71 - - Annual Debt Portfolio Yield of 16.6% - - HRZN Ends Year with Committed Backlog of $218 Million - - Declares...

BioVaxys acquires IMV's immunotherapy assets and IP

VANCOUVER, BC, Feb. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. announced that it has executed the definitive  Asset Purchase Agreement dated February 11th, 2024 to acquire the entire...